These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27721905)

  • 61. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
    Guidelli GM; Viapiana O; Luciano N; De Santis M; Boffini N; Quartuccio L; Birra D; Conticini E; Chimenti MS; Bazzani C; Bruschi E; Riva M; Canziani LM; Bianchi G; Pozzi MR; Limonta M; Gorla R; Perricone R; Frediani B; Moscato P; De Vita S; Dagna L; Rossini M; Selmi C
    Clin Exp Rheumatol; 2021; 39(4):868-873. PubMed ID: 33338001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study.
    Miyashiro M; Asano T; Ishii Y; Miyazaki C; Shimizu H; Masuda J
    Drugs Real World Outcomes; 2024 Jun; 11(2):285-297. PubMed ID: 38598110
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Methotrexate: optimizing the efficacy in rheumatoid arthritis.
    Braun J
    Ther Adv Musculoskelet Dis; 2011 Jun; 3(3):151-8. PubMed ID: 22870474
    [TBL] [Abstract][Full Text] [Related]  

  • 66. No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis.
    Baradat C; Degboé Y; Constantin A; Cantagrel A; Ruyssen-Witrand A
    RMD Open; 2017; 3(1):e000352. PubMed ID: 28270933
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment strategies are more important than drugs in the management of rheumatoid arthritis.
    Drosos AA; Pelechas E; Voulgari PV
    Clin Rheumatol; 2020 Apr; 39(4):1363-1368. PubMed ID: 32088801
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent.
    Senbel E; Durand F; Roux B; Badaoui FZ; Fautrel B
    Rheumatol Ther; 2021 Jun; 8(2):921-935. PubMed ID: 33939171
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
    Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
    Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Switching biologics in the treatment of psoriatic arthritis.
    Merola JF; Lockshin B; Mody EA
    Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian Settings.
    Perrone V; Losi S; Rogai V; Antonelli S; Fakhouri W; Giovannitti M; Giacomini E; Sangiorgi D; Degli Esposti L
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073179
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs.
    Momen Majumder MS; Hasan ATMT; Choudhury MR; Ahmed S; Miah MT; Amin MR; Shahin MA; Islam A; Shazzad MN; Hassan MM; Ahmedullah AK; Rahman MM; Yesmeen S; Uddin T; Haq SA
    Cureus; 2024 Apr; 16(4):e59395. PubMed ID: 38707172
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?
    Aletaha D; Smolen JS
    Rheum Dis Clin North Am; 2019 Aug; 45(3):315-324. PubMed ID: 31277746
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.